+

WO1994011497A1 - Procede d'obtention d'une immunosuppression selective a l'aide de lectines apparentees a hl-60 - Google Patents

Procede d'obtention d'une immunosuppression selective a l'aide de lectines apparentees a hl-60 Download PDF

Info

Publication number
WO1994011497A1
WO1994011497A1 PCT/US1993/011107 US9311107W WO9411497A1 WO 1994011497 A1 WO1994011497 A1 WO 1994011497A1 US 9311107 W US9311107 W US 9311107W WO 9411497 A1 WO9411497 A1 WO 9411497A1
Authority
WO
WIPO (PCT)
Prior art keywords
lectin
cells
pharmaceutical composition
amino acid
acid sequence
Prior art date
Application number
PCT/US1993/011107
Other languages
English (en)
Inventor
Jeffrey J. Seilhammer
Glenn Nedwin
Tim Bringman
Pierre-Olivier Couraud
Original Assignee
Incyte Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Pharmaceuticals, Inc. filed Critical Incyte Pharmaceuticals, Inc.
Priority to AU56085/94A priority Critical patent/AU5608594A/en
Publication of WO1994011497A1 publication Critical patent/WO1994011497A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4726—Lectins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell

Definitions

  • the invention relates to the use of
  • carbohydrate-binding proteins as regulators of cell differentiation and immunity.
  • the active ingredient is a soluble lectin of about 14 kD or a fragment thereof which can be isolated from human HL-60 cells or placenta tissue.
  • Recombinant materials and methods to produce these inventive lectins are also provided.
  • invention is also directed to methods to treat autoimmune diseases and to prevent transplant rejection.
  • Lectins are defined as proteins which specifically bind carbohydrates of various types.
  • Sparrow, C.P., et al., J. Biol. Chem. (1987) 252:7383-7390 describe three classes of soluble lectins from human lung, one of 14 kD, one of 22 kD, and a third of 29 kD. All of these lectins are specific to ⁇ -D-galactosides.
  • the carbohydrate specificities of the 14 kD class are for the most part similar, but the larger molecular weight species tend to have different specificities.
  • Other species are also noted as showing more than one soluble ⁇ -D-galactoside-binding lectin, including mouse (Roff, C.F., et al., J. Biol. Chem.
  • ligand specificity is considerably different, and the approximately 14 kD group appears distinct from the 22 kD and 29 kD representatives described by Sparrow, et al., supra.
  • ⁇ -D-galactoside containing moieties specifically to certain ⁇ -D-galactoside containing moieties and are found in a wide range of mammalian, invertebrate, avian, and even microbial sources. All of the lectins in this class appear to contain subunits with molecular weights of about 12-18 kD. Furthermore, these lectins can be readily classified by virtue of a simple diagnostic test: their ability to agglutinate
  • trypsin-treated rabbit red blood cells is specifically inhibited by certain ⁇ -D-galactose-containing moieties.
  • lectins themselves agglutinate
  • the agglutination can be inhibited by, for example, lactose, thiodigalactoside and certain other ⁇ -D-galactose containing moieties.
  • lactose thiodigalactoside
  • ⁇ -D-galactose containing moieties Other common characteristics include no requirement for metal ions in effecting agglutination and the required presence of a reducing agent such as a thiol.
  • sequences of several animal lectins including those from chick, eel, human placenta, human lung, and two
  • hepatoma-derived lectins (all of these lectins described as referenced above). Only the chicken lectin contains an "N-linked" glycosylation site, which is not conjugated to saccharide. No known mammalian lectin in this family has an N-linked glycosylation site.
  • the preferred lectins of the present invention are isolated from the human promyelocytic leukemia cell line HL-60 or human placenta tissue. Lectins have been isolated from the HL-60 cell line by others, but they are markedly different from the lectins of the present invention. Paietta, E., et al., Cancer Res. (1988)
  • intercellular communication are so subtle in nature and so critically tuned to the host environment, subtle changes in structure can result in a wide range of such regulators with differing therapeutic and diagnostic uses.
  • a number of members of the class of ⁇ -D-galactose-binding soluble lectins weighing approximately 14 kD are known in the art. However, while these lectins have some similarities, they are not interchangeable therapeutically or diagnostically.
  • lectins which can be glycosylated the extent and nature of the glycosylation can be manipulated to alter important lectin properties (e.g., circulating half-life, metabolism in vivo, solubility, stability, and specific activity).
  • Levy et al. (Eur. J. Immunol. (1983) 13:500- 507) reported that electrolecrin binds to peripheral blood and lymph node lymphocytes and is mitogenic. When Levy et al. administered electrolectin to rabbits
  • autoimmune diseases such as myasthenia gravis (MG), rheumatoid arthritis (RA)
  • systemic lupus erythematosus SLE
  • MS multiple sclerosis
  • juvenile arthritis Typically MG, RA, SLE and MS are treated first with corticosteroids.
  • Steroidal drugs have been used for decades and their adverse effects are well known. Adverse effects that can be anticipated in all patients on prolonged steroid therapy include osteoporosis, truncal obesity, impaired wound healing, infections and growth arrest in children. Less frequently occurring adverse effects include myopathy, hypertension, hyperlipidemia, diabetes mellitus and cataracts. Severe side effects may develop and require patient monitoring. These include glaucoma, intracranial hypertension, intestinal perforation, and ulcers.
  • MG, RA, SLE or MS become refractory to steroids, then increasingly toxic drugs are employed, including azathioprine, methotrexate and
  • azathioprine inhibits DNA synthesis, thus lowering numbers of T and B lymphocytes.
  • azathioprine inhibits the mixed lymphocyte reaction and immunoglobulin production, but does not consistently affect delayed-type
  • azathioprine is pancytopenia, particularly lymphopenia and granulocytopenia. Consequently, there are increased risks of viral, fungal, mycobacterial and protozoal infections. An increased rate of lymphoreticular
  • Methotrexate inhibits folic acid synthesis and is cytotoxic, suppressing bone marrow. At the low doses used for RA, methotrexate should not decrease the numbers of lymphocytes; but IgM and IgG are reduced. Side effects include pneumonia, nausea, stomach upsets, mouth ulcers, leukopenia, thrombocytopenia, and a form of hepatic fibrosis, which can only be diagnosed by liver biopsy.
  • Cyclophosphamide is also used in RA therapy. It is metabolized in the liver to a compound which crosslinks DNA. Cyclophosphamide is cytotoxic, with severe toxicity seen even at low doses. It affects RA by reducing numbers of B- and T-lymphocytes, decreasing the immunoglobulin concentrations and diminishing B-cell responsiveness to mitogenic stimuli. Hair loss, infections, and powerful nausea are common. With prolonged administration, patients develop malignancies at an increased rate.
  • Cyclosporin does not suppress white cells, but it is a powerful immunomodulatory drug and is effective in treating rheumatoid arthritis. However, an important side effect is renal toxicity.
  • Monoclonal antibodies to CD4 have been used in autoimmune diseases, but they cause nonspecific
  • Gold salts are given intramuscularly and their effect may not be seen for months.
  • Adverse effects of gold treatment include bone marrow aplasia,
  • Antimalarials exert several effects on the immune system without decreasing the numbers of lymphocytes. The most serious side effects of antimalarials include retinal pigment
  • Sulfasalazine has several effects which contribute to its effect on RA; however, it has numerous side effects.
  • Penicillamine has been successfully used in RA; however, its numerous side effects have limited its use.
  • Penicillamine has been reported to cause other autoimmune diseases, including myasthenia gravis and SLE.
  • transplanted including the kidneys, heart, lungs, skin, bone marrow, cornea, and liver.
  • Drugs frequently used in transplant patients include cyclosporin, azathioprine, rapamycin, other macrolides such as FK506, prednisone, methylprednisolone, CD4 antibodies and cyclophosphamide. Frequently these drugs must be given in higher doses and for longer periods to transplant patients than to
  • the present invention is directed to a
  • the active agent is a soluble lectin of MW of about 14 kD or a fragment thereof, wherein the lectin or fragment (1) binds ⁇ - galactoside-containing moieties whether Ca +2 is present or not, (2) stimulates hemagglutination of trypsinized rabbit erythrocytes in standard lectin assays which is inhibited by lactose or thiodigalactoside, (3) provides an amino acid sequence containing at least one N- glycosylation site and at least 90% homologous to the amino acid sequence shown in positions 2-135 of Figure 1 or the relevant portions thereof, and wherein the active ingredient is mixed with a carbohydrate and at least one pharmaceutically acceptable excipient.
  • the composition can also contain one or.more general immune system suppressants such as cyclosporin.
  • the invention also provides recombinant materials and methods to produce these new lectins.
  • the invention is directed to methods to treat autoimmune diseases and to prevent transplant rejection.
  • the efficacy of these methods results from the surprising ability of the inventive lectin to suppress the host immune response to both autoimmunogens and foreign tissue.
  • Figure 1 shows the cDNA sequence and deduced amino acid sequence of both the HL-60 and placenta lectin. Superscript numbers correlate to the
  • Figure 2 shows immunostaining of thymic epithelium by anti-lectin and anti-cytokeratin
  • Figure 3 shows an electrophoresis gel with staining in a location indicative of mRNA for the inventive lectin in thymic epithelial cells.
  • Figure 4 shows the percentage of ARR T-cells that adhered to thymic epithelial cells with and without enzyme treatment.
  • Figure 5 shows results of hemagglutinin bioassay of purified lectins from human placenta, HL-60 cells and E. coli cells transfected with vectors
  • Figure 6 shows the effect of several doses of the inventive lectin on the primary immune response to tetanus toxoid.
  • Figure 7 shows the effect of several doses of the inventive lectin on the primary immune response to pneumococcal polysaccharide.
  • Figure 8 shows the effect of several doses of the inventive lectin on the primary immune response against the Torpedo receptor.
  • Figure 9 shows the effect of several doses of the inventive lectin on the primary immune response against mouse skeletal muscle receptor in animals immunized with the Torpedo receptor.
  • Figures 10 and 11 show the results of the treatment with, the inventive lectin on clinical symptoms in a rat model for multiple sclerosis.
  • Figure 12 is a graphical representation of the effect of recombinantly produced lectin in a rat model for multiple sclerosis.
  • Figure 13 shows the effect of the recombinantl produced lectin on a relapse murine model for multiple sclerosis.
  • Figure 14 is a graphical comparison of the survival of skin allografts when rats received lectin and placebo.
  • Figure 15 is a graphical comparison of the percentages of migrating lymphoid cells in various organs after heart allografts when rats received lectin and vehicle.
  • Figure 16 is a graphical comparison of the percentages of migrating lymphoid cells in various organs after skin allografts when rats received lectin and vehicle.
  • the invention is directed to pharmaceutical compositions wherein the active ingredient is a soluble, 14 kD lectin or fragment thereof.
  • the preferred lectin of the invention is isolatable from HL-60 cells as well as from human placental tissue.
  • the lectins of this invention are soluble, capable of binding ⁇ -galactoside- containing moieties independent of the presence or absence of calcium ion, capable of stimulating
  • One embodiment consists essentially of the amino acids shown in Figure 1 numbered from 2-135 which contain at least one tripeptide sequence, Asn-X-Thr or Asn-X-Ser.
  • this tripeptide sequence provides a
  • a preferred embodiment of this invention provides a lectin with at least one glycosylation site, exemplified by Asn-Leu-Thr. Most preferably, the glycosylated tripeptide starts at position 96 of the illustrated HL-60 lectin.
  • the native material at least in part, apparently is not glycosylated at this site; however, when the lectin is appropriately produced in certain recombinant hosts, the site can be glycosylated. Accordingly, the invention provides for glycosylated forms, so long as glycosylation does not destroy
  • the preferred lectins include the peptide comprising positions 2-135 in Figure 1 or the naturally occurring mutants or allelic variations thereof. It is well understood that proteins produced by organisms do not necessarily remain stable in the form studied, but that the genes encoding them are subject to occasional natural mutations and variations that change one or a few amino acids; therefore, the proteins resulting from natural mutation are included in the invention, so long as the mutation does not destroy activity. An allelic mutation changing as many as 15 amino acids is not expected to destroy the activity of the lectin.
  • the allelic mutation would change no more than about 10 amino acids. Most preferably, only about five amino acids would be changed by an allelic mutation.
  • the fragments in order to be included within the scope of the invention, must exhibit the specific properties characterizing the class, i.e., they must be soluble, capable of binding 0-galactoside-containing moieties independent of the presence or absence of calcium ion, capable of stimulating hemagglutination of trypsinized rabbit erythrocytes in standard lectin assays which can be inhibited by lactose or thiogalactoside, and at least 90% homologous to the relevant portion of positions 2-135 of Figure 1. While a specific minimum fragment length cannot now be identified, it is within ordinary routine experimentation to assay candidate fragments for these activities. It is well understood that only portions or fragments of a particular protein can have the activity of the complete natively produced protein.
  • HL-60 cells and placenta tissue produce the preferred 14 kD ⁇ -gal binding lectin of the invention; this lectin is representative of the inventive class of 14- ⁇ -gal soluble lectins, one embodiment of which has at least one glycosylation site.
  • the phrase "14- ⁇ -gal mammalian lectin containing at least one glycosylation site" refers to a class of peptides having the characteristics of the group of lectins exemplified by the HL-60 lectin of Figure 1 which contain at least one tripeptide sequence, Asn-X-Thr or Asn-X-Ser, which provides a glycosylation site.
  • a peptide must exhibit the following biological properties:
  • a molecular weight of the nonglycosylated protein is approximately 14 kD. As a practical matter. the molecular weight ranges from about 12-18 kD when it is measured by various techniques.
  • the inventive lectin causes hemagglutination of trypsinized rabbit erythrocytes in standard lectin assays, in which the stimulation of agglutination is inhibited by moieties containing the ⁇ -galactoside linkage, such as lactose and thiogalactoside. Hemagglutination can occur without a reducing agent, which is capable of maintaining thiol groups in the reduced form, but hemagglutination occurs without metal ions, in particular calcium ions.
  • inventive lectins and fragments have at least 40% homology with the HL-60 lectin of Figure 1, preferably at least 75% homology, more preferably over
  • glycosylation site is at residues 96-99, as is the case for the lectin of Figure 1.
  • the glycosylation site can be within, at most, a four-amino acid spacing upstream or three-amino acid spacing downstream, i.e., between residues 92 and 101 inclusive.
  • Other preferred locations include those which contain Asn, X (any amino acid), and Ser/Thr residues in any of the animal lectins at nonconserved regions.
  • the most preferred embodiment of the 14- ⁇ -gal lectins containing glycosylation sites is that of the HL-60 lectin of Figure 1, particularly the lectin from HL-60 cell or placental tissue sources or a lectin from the naturally occurring mutants and allelic variants thereof.
  • glycosylation of these inventive lectins can be any glycosylation of these inventive lectins.
  • the lectins of the invention can be isolated from native sources, synthesized, or produced by
  • the lectins and fragments of the invention can be prepared, if desired, by standard solid phase or other peptide synthesis methods. This mode of preparation is generally considered most suited for smaller peptide fragments. Although this method is clearly within the skill of the art with respect to the full-length lectin sequences, such as that shown in Figure 1, part or all of the molecule can more conveniently be synthesized using recombinant techniques.
  • the DNA which encodes the inventive lectin or fragment is mobilized by ligating the appropriate sequence to control sequences regulating expression, transfecting the resulting expression systems into appropriate hosts, and culturing the transformed or transfected hosts under conditions favorable for the expression of the DNA.
  • an intronless DNA is required; however, in eucaryotes a genomic DNA can also be used.
  • Genomic DNA encoding the HL-60 and placental lectin and its naturally occurring mutants and allelic variants can be recovered from the HL-60 or placental genome using the cDNA of Figure 1 as a probe.
  • the lectin-encoding sequence can be ligated into the expression system preceded by an ATG to obtain the lectin as a mature protein.
  • signal sequences known to be operable in the intended host such as the penicillinase or alkaline phosphatase system in bacteria, the alpha-factor system in yeast, or various hormone signal sequences in mammalian cells can be used to effect secretion by constructing the expression system with the DNA encoding signal in reading phase with the lectin DNA.
  • the lectin could also be produced as a fusion protein by ligating the coding sequence into reading frame with an additional coding sequence if desired.
  • E. coli are preferred, although other bacterial strains, such as Bacillis and
  • Suitable control systems include, but are not limited to, promoters associated with bacterial proteins such as ⁇ -lactamase and lactose (lac) promoter systems (Chang et al., Nature (1977)
  • yeast systems includes, but is not limited to, the promoter for 3-phosphoglycerate kinase (Hitzeman et al., J. Biol. Chem. (1980) 255:2073), the enolase gene promoter (Holland, M.J., et al., J. Biol. Chem. (1981) 256:1385). and the leu2 gene obtained from YEp 13 (Broach, J., et al., Gene (1978) 8:121).
  • the promoter for 3-phosphoglycerate kinase Hitzeman et al., J. Biol. Chem. (1980) 255:2073
  • the enolase gene promoter Holland, M.J., et al., J. Biol. Chem. (1981) 256:1385).
  • leu2 gene obtained from YEp 13 (Broach, J., et al., Gene (1978) 8:121).
  • promoters operable in such cells include, but are not limited to, viral promoters such as the SV40 promoter (Fiers et al., Nature (1978) 273:113) and promoters derived from adenovirus, bovine papilloma virus, Rous sarcoma virus, and so forth. Also usable are regulatable promoters such as the metallothionein I or
  • the appropriate coding sequences are ligated to the control sequences in operable configuration and in suitable vectors for transfection into the intended host.
  • the vectors include, but are not limited to, plasmids, virus particles and phages depending on the intended host and the mode of transformation.
  • Transformation includes all forms of causing uptake of foreign DNA by a host cell including viral infection, transduction, conjugation or, probably most common, induction of uptake in vitro by transfection using transfecting agents such as calcium chloride or
  • the transformed cells are then screened for those which contain the desired DNA and the successful transformants are cultured under conditions which affect the expression of the coding sequences.
  • the lectin produced is then purified from the medium (if the
  • construction results in secretion) or from the lysed cells (if the construction results in an intracellular protein).
  • the lectin can be purified by standard methods, including extraction in lactose solution followed by
  • chromatographic procedures includes chromatography on lactose sepharose gels, a sephadex S-200 HR column, or a lactose-HEMA column. After using any of these chromatography
  • the presence of the protein in the active fractions can be easily detected by the ability of the fraction, after removal of the lactose, to cause
  • hemagglutination of trypsinized rabbit erythrocytes wherein the hemagglutination is inhibited by millimolar concentrations of lactose or thiodigalactoside.
  • the lectins of the invention can be used in conventional ways to raise antisera reactive with, and specific for, these lectins.
  • An antibody "specific for" the referenced lectin means an antibody which is
  • antibodies raised against this lectin are likely to cross-react with other inventive lectins. However, by producing monoclonal antibodies with respect to this lectin, antibodies specific to one particular embodiment or to a selected group of inventive lectins can be generated. In addition, antibodies specific for various glycosylated forms can also be prepared.
  • Antibodies can be prepared using known techniques with specificities for any particular member of the inventive 14- ⁇ -gal lectin class, including those with at least one glycosylation site and in
  • the antibodies within the scope of the invention are those which are reactive with one or more members of the lectins of the invention, but the antibodies are not cross-reactive with the lectins presently known in the art. Also included in the scope of the invention are antisera raised by any of the lectins of the invention, since these antisera are unique to these lectins even if they contain antibodies which are cross-reactive in some measure with known lectins.
  • lectins and fragments of the invention and their compositions are useful in a range of therapeutic and diagnostic applications. In general, these peptides and proteins are particularly useful as
  • the inventive lectins and fragments can be used in the treatment of autoimmune diseases such as myasthenia gravis.
  • autoimmune diseases such as myasthenia gravis.
  • Other autoimmune diseases which are subject to treatment by these lectins include myasthenia gravis.
  • inventive lectins can also be useful in controlling allergic reactions.
  • inventive lectins and fragments can be administered in conjunction with various surgical transplantations including skin allografts, bone marrow transplants, and organ transplants such as kidney, heart, liver or lung transplants.
  • various surgical transplantations including skin allografts, bone marrow transplants, and organ transplants such as kidney, heart, liver or lung transplants.
  • the lectins and fragments of the present invention can be administered along with amounts of known general immunosuppressants that enhance their effects.
  • suitable general immunosuppressants include, for example, cyclophosphamide, prednisone, cyclosporin, rapamycin, other macrolide derivatives such as FK506, azathioprine, mycophenolic acid, anti-Tac, lymphocyte immune globulin, and OKT3 antibodies.
  • the inventive lectins and fragments thereof can be administered simultaneously or
  • Suitable targets for lectins are those cells of mammalian subjects with galactose-terminating ligands. These lectins are coupled to a drug, for example, cytotoxic or therapeutic agents, or to a label, by methods in the art.
  • antibodies specific for the inventive lectins are useful in targeting drugs or labels to tumors, since the level of certain lectins increases on the cell surface in metastatic cancer.
  • Anti-lectin antibodies are coupled to the drug, for example, a cytotoxic or
  • the label coupled to the lectin or anti-lectin can be administered to a living mammalian subjects (in vivo use) or used in in vitro tests, for example, as part of a test kit.
  • the inventive lectins behave as immunomodulating agents and regulate the immune system by binding activated lymphocytes to other activated lymphocytes and to endothelial cells, for example on the inside of blood vessels.
  • Surface glycoproteins on resting lymphocytes contain terminal sialic acid
  • activated lymphocyte glycoproteins are desialylated to expose galactose.
  • inventive lectin is specific for activated T-cells and causes them to agglutinate or to adhere to endothelial cells. It is believed that these interactions may inhibit or modify T-cell migration, e.g. extravasation from the
  • the inventive lectin may affect the immune response by another route.
  • Antibodies specific for the inventive lectin have been observed reacting with human thymic tissue, particularly thymic cortical epithelial cells whose interaction with immature cortical thymocytes is crucial in deleting auto-reactive T-cells.
  • thymic tissue particularly thymic cortical epithelial cells whose interaction with immature cortical thymocytes is crucial in deleting auto-reactive T-cells.
  • the thymus typically atrophies early in life and is not known to play an active role in adult autoimmune
  • administration of the inventive lectin may possibly increase thymic deletion of autoreactive T- cells.
  • the lectins and fragments are formulated in a manner suitable for the desired mode of administration using formulation technology known in the art as described, for example, in Remington's Pharmaceutical Sciences, 17th edition, Mack Publishing Co., Philadelphia, PA.
  • Typical formulations for injection include admixture with physiological buffer for injection such as Hank's solution or Ringer's
  • a particularly preferred method of formulation provides for long term storage of the soluble lectin of this invention in the lyophilized, or freeze-dried, form.
  • Lyophilization is preferably conducted in the presence of a concentration of a carbohydrate which is effective to stabilize the lectin during the lyophilization process and at a relatively low pH of about 5. This pH appears to minimize oxidation.
  • a low ionic strength buffer is also preferred.
  • Suitable protective carbohydrates include, but are not limited to,
  • carbohydrates are lactose and maltose. The most
  • the preferred protective carbohydrate is lactose. Because the lyophilized product is used in a pharmaceutical composition, the protective carbohydrate must be
  • the effective concentration of the protective carbohydrate can be 1-40% wt. /volume but is preferably around 5-15%, and even more preferably around 10%.
  • the buffer is bicarbonate, gluconate, lactate, acetate or phosphate.
  • the buffer is citrate. It is preferred that the buffer concentration be about 5-20 mM, more preferably 7-12 mM, and most preferably about 10 mM. Other conditions of lyophilization can also be used; however, it has been found that the presence of about 10% lactose in about 10 mM citrate and a pH of 5 are particularly favorable conditions.
  • the dosage level and manner of administration of the lectins and fragments of the invention depends on the indication and the subject, as well as the severity of the condition to be treated.
  • a higher dose is required than when active fragments of the lectin are administered.
  • Some indications for use such as transplantation rejection, particularly full-blown rejections) require higher doses than to others (such as rheumatoid
  • the subject who receives the inventive lectin can be a mammal, bird or other vertebrate, because the lectins of mammals, birds, eels, and fish have been found to be related.
  • the term subjects refers to mammalian subjects, including humans, farm animals, sport animals and pets. Farm animals include, but are not limited to, cows, hogs and sheep. Sport animals include, but are not limited to, dogs and horses.
  • the category pets includes, but is not limited to, cats and dogs. Smaller animals generally require somewhat higher doses per kilogram.
  • Preferred dose levels range from about 0.004 mg/kg/day to about 2 mg/kg/day.
  • inventive lectins or fragments are administered in a manner suitable for peptides or proteins--i.e., by injection or by other parenteral routes including transmembrane or transmucosal
  • E. coli containing an expression plasmid in which the DNA to be expressed is that shown in Figure 1, were grown in Luria broth (LB) to stationary phase. In general, about 5 g of cells wet weight per liter of broth were typically obtained. The cells were then frozen and the lectin was extracted by purification procedures.
  • LB Luria broth
  • the frozen cell samples were thawed in ice overnight or under cool running water to expedite the thawing.
  • the cells were collected in a beaker and slowly mixed with a 15 mM ⁇ -mercaptoethanol (B-ME) buffer to form a thin paste having a density of approximately 0.1 to 0.3 g/ml.
  • the buffer was a solution comprised of 0.02M Tris, 0.15M NaCl, 0.002M EDTA, and 15mM
  • the cold environment is a room that is maintained between 2 and 6° C.
  • the cells and buffer were mixed for a time period as long as two hours until a homogeneous, lump-free, cell suspension results.
  • the cell suspension was passed twice through a high pressure Microfluidics homogenizer, operated at 15,000 psi.
  • the homogenizer was packed in ice to prevent heating of the cell suspension.
  • Tris buffered saline (TBS) was used to recover the disrupted cell product obtained from the homogenizer.
  • the disrupted cells were next placed in an RC5B centrifuge (DuPont de Nemours, Wilmington, DE) at the maximum speed (approximately 8000 rpm) for thirty minutes to separate cell debris.
  • the centrifuged cell product was next decanted to separate the protein supernate from the cell pellets.
  • the cell pellets can be quick frozen on dry ice for later possible application.
  • PEI polyethylenimide
  • PEI can be added before the first centrifugation step, instead of before the second centrifugation step, which can then be
  • An alternative chromatographic procedure involves ion-exchange chromatography on a Sephadex S-200 column (Pharmacia).
  • the column is depyrogenated using sodium hydroxide washes of decreasing concentration.
  • the S-200 column is next equilibrated with 10 mM citrate, having a pH of 5.0.
  • the yellow/tan supernate is loaded onto the column at a rate of approximately 15 cm/hr.
  • the supernate can be loaded at a rate up to 6 % by volume of the total solvent exchange.
  • the product concentration at loading should be as high as possible to eliminate or minimize the need to further concentrate the eluted product.
  • the eluted product is diluted in a 1:1 ratio with sterile-filtered 10% Lactose in 10 mM Citrate having a pH of 5.0.
  • a further alternative chromatographic procedure includes the use of a Lactose-HEMA column.
  • the eluted product obtained from the above chromatographic procedure was stored in small vials, with about 1 to 5 ml of the product in the appropriately sized vial.
  • the vials were sterilized prior to filling by heating the vials to about 150°C for a minimum of 4 hours. Any leak tight caps, such as grey split stoppers, can be used to contain the product within the vial.
  • the product was next lyophilized using a Virtis lyophilization chamber or unit.
  • the vials containing the product were placed in the unit's chamber and frozen to -30°C. This temperature was maintained for at least 3 hours.
  • a vacuum was applied to the chamber and the pressure was reduced to less than about 100 torr and preferably about 15 torr.
  • the Virtis unit was maintained at -30°C and 15 torr for at least two hours.
  • the unit and vials were brought to 0°C and maintained at this temperature for at least two hours.
  • the temperature was further increased to 30°C in 5°C increments over a six hour period. Once the 30°C temperature was reached, the unit was maintained at 30°C for at least two more hours.
  • the vials were then sealed under vacuum with stoppers and aluminum seals, over which vial caps were crimped.
  • Rat lymph node lymphocytes and human T-cells of the Jurkat line (10 7 /ml in Dulbecco's modified Eagle medium (MEM) with 5% fetal bovine serum (FBS) ) were treated with 250 ⁇ g/ml of the lectin of Example 1, with the lectin plus 1 mM lactose, or with no additions and subsequently were placed on ice for 30 min.
  • the lectin severely agglutinated the T-cells and moderately clumped the rat lymphocytes.
  • T-cells bound to the endothelium of inflamed cerebral blood vessels. T-cells treated with lectin did not bind to the endothelium, possibly because the T-cells were agglutinated and unavailable to react. Lectin strongly accentuated the binding of rat lymphocytes to the
  • lectin enhances binding of rat lymphocytes to vascular endothelium by reacting with both the endothelium and with the lymphocytes and serving as a molecular bridge. The lectin did not similarly bind
  • T-cells to endothelium, possibly because the T-cells were so thoroughly agglutinated that no free cells were available to bind the endothelium.
  • lymphoid organs lymph nodes and Peyer's patch
  • Lectin had no noticeable effect on rat lymphocytes; however, because control level binding was very low, this result cannot be relied on.
  • anti-lectin antiserum was prepared by injecting the inventive recombinant lectin into rabbits. Polyclonal antiserum specific for the inventive lectin was obtained from the immunized rabbits. Slides were made of sections of human thymic cortex and of cultured thymic epithelial cells. These sections of human thymic tissue and cultured thymic epithelial cells were incubated with the rabbit anti-lectin antisera.
  • the cross-reactivity was detected at a dilution of 1:1000 by labeling the antibody-coated sections with goat anti- rabbit horseradish peroxidase and adding substrate.
  • the thymic sections were examined by microscopy and had highly stained thymic cortical epithelial cells.
  • the cultured thymic epithelial cells were also highly
  • recombinant lectin has been localized to epithelial cells in human thymic tissue.
  • protein extracts of cultured thymic epithelial cells stained positively with the rabbit-polyclonal antiserum on Western blots in an immunoreactive band which comigrated with the inventive lectin.
  • thymic cortical epithelial cells have a protein with a molecular weight, antigen reactivity and DNA sequence similar to those properties of the inventive lectin.
  • inventive lectin appears to affect thymocyte maturation.
  • immature cortical thymocytes show much higher levels of the galactose ligand which is recognized by the inventive lectin. This further supports interaction of the
  • inventive lectin with immature thymic cells rather than an effect on mature T-cells.
  • galactose-terminating ligands are present on the cell surfaces of migrating leukocytes and could be responsible for leukocyte recognition by lectincontaining homing receptors. Because the inventive lectins are specific for galactose ligands, the inventive lectins should affect the extravasation caused by
  • T-cell lines MOLT4 and ARR a T-cell line with sialic-acid-terminating glycoproteins
  • neuraminidase which cleaves terminal sialic acids from the glycoproteins on ARR cells and leaves terminal galactose
  • galactosidase endolactosaminidase or no enzyme.
  • the cells were incubated with and without lectin. All the treatment and control groups of T-cells were layered over thymic epithelial cells, incubated and washed as
  • Biological activity of the inventive 14 kD lectins 1) isolated from HL-60 cells, 2) isolated from placenta tissue or 3) prepared recombinantly from E. coli cells transfected with lectin cDNA operably linked to a secretion signal was ascertained by agglutination of trypsinized rabbit erythrocytes.
  • the top row shows a Concanavalin A control with an agglutination end-point at 1.5 ⁇ g/ml.
  • the lower six rows show the three purified inventive 14 kD lectins incubated with varying concentrations of completing sugars, ⁇ - lactose and thiodigalactoside, which are known to be potent inhibitors of the 14 kD placental lectin.
  • erythrocytes at concentrations greater than 0.31 mM and ⁇ -lactose inhibited agglutination at concentrations greater than 1.25 mM.
  • EMG Experimental autoimmune myasthenia gravis
  • AChR acetylcholine receptors
  • T helper cells which produce acetylcholine receptor antibodies.
  • the disease is induced in mice by injection of acetylcholine receptor.
  • the acetylcholine receptor is obtained from the electric organ of the ray Torpedo marmorata and purified by affinity chromatography on Naja naja siamensis neurotoxin crosslinked to
  • mice Young adult female BALB/c and C57B/6 mice (2-4 months of age) were used because they differ in EAMG susceptibility. The mice were injected subcutaneously with 10 ⁇ g of purified acetylcholine receptor, in
  • a cholinergic receptor (AChR) extract was prepared as described by Lefvert, A.K. et al., Scand. J. Immunol, supra for determination of total AChR content and Ig-complexed AChR content, as described therein.
  • AChR content known portions of the AChR extracts were incubated with a tenfold excess of 125 I-alpha-bungarotoxin for 1 hour at 37oC so as to label the receptor for quantitation. The mixture was subjected to gel filtration on Sephacryl G200 to separate free and bound toxin. To determine the amount of AChR complexed to IgG or IgM antibodies, the extract was incubated with a ten-fold excess of labeled bungarotoxin overnight at 4°C; anti-mouse IgG or IgM was then added and the samples incubated overnight at 4°C, followed by separation of the precipitates, washing and counting.
  • mice Three BALB/c female mice (7-8 weeks old) were injected intraperitoneally with 5 ⁇ g of AChR antibody, tetanus toxoid or pneumococcal polysaccharide,
  • mice were injected intravenously with the same amount of antigen in 0.15 M sodium phosphate buffer, pH 7.4. Tetanus toxoid was obtained from the Swedish
  • mice of the same strain were similarly immunized with these antigens in combination with 15 ⁇ g of the recombinant lectin;
  • the animals were sacrificed 4 days after the booster injection and spleen cells (10 cells) were fused with the nonsecreting B-lymphocytoma cell line SP2-OAg14 (2 x 10 7 cells).
  • the cell mixture was distributed in 6 x 96 Costar tray wells (2 x 10 5 cells/well) with a feeder layer of mouse peritoneal macrophages (5 x 10 5
  • coadministration of lectin is effective in reducing the number of primary clones producing antibodies against AChR and tetanus toxoid. Coadministration of lectin reduced only slightly the number of hybridomas producing antibodies immunoreactive with the polysaccharide. It is believed that the B-cell response to the AChR and tetanus toxoid antigens is T-cell dependent, while that to the polysaccharide is independent of T-cells.
  • microtiter wells were coated overnight with 100 ⁇ l of a solution containing 5 ⁇ g/ml of purified receptor as prepared in Example 8, Part A, and incubated with serum (diluted 1/25) for 3 hours at 37oC. After washing, the plates were incubated for 3 hours at 37°C with alkaline phosphatase-conjugated goat anti-mouse
  • antibodies against mouse AChR antibodies were determined using as antigen a complex between a partially purified normal mouse skeletal muscle receptor and 125 I-alpha-bungarotoxin. The results were expressed in moles of toxin receptor precipitated by 1 liter of serum, after subtraction of the mean +4SD of cumulated results from a normal population (more than 50 mice).
  • microtiter wells were coated overnight with 100 ⁇ l of a solution containing 5 ⁇ g/ml of the antigen and incubated with serum (diluted 1/200) for 3 hours at 37oC. After washing, the plates were
  • the cut-off limit was the mean +4SD of cumulated values obtained with this normal serum pool. The values were expressed in milliabsorbance units after subtraction of the mean +4SD of the normal serum pool.
  • mice Groups of BALB/c mice were immunized with tetanus toxoid, pneumococcal polysaccharide, ray Torpedo receptor and mouse receptor without and with various doses of recombinant lectin. Blood was obtained after 3 days and again after 1, 2, 3 and 4 weeks and antibody levels were determined as described above.
  • EAE Experimental autoimmune encephalomyelitis
  • GPBP guinea pig myelin basic protein
  • CFA Complete Freund's Adjuvant
  • T-cells specific for GPBP in immunized rats recognize amino acid residues 72-89 of GPBP and have the ability to transfer both clinical signs of EAE and delayed-type hypersensitivity reaction to GPBP to other animals.
  • EAE was induced by injection of GPBP/CFA as described above.
  • intravenous administration of lectin was started at day 0 relative to 50 ⁇ g GPBP/CFA injection, with additional lectin treatment at days 3 and 6.
  • the severity of the disease was determined clinically and histologically:
  • the 0, 3, 6-day protocol resulted in a slight delay in the onset of sickness; the sickness was less severe; the duration of sickness was shorter; and weight loss was less.
  • Figure 10 shows the severity of the disease with lectin dosages ranging from 10-1500 ⁇ g intraperitoneally.
  • Figure 11 shows a summary representation of these results computed on day 12. As determined from Figures 10 and 11, a daily dosage of 500 ⁇ g appears optimal for ameliorating the symptoms of experimental autoimmune encephalitis.
  • lymph nodes draining the site of injection were collected and tested for a proliferative response to GPBP, purified protein derivative (PPD), and the T-cell mitogen, Concanavalin A (ConA). Consistent with the DTH test, lymph node cells of the lectin-treated rats had low or absent responses to both GPBP and PPD relative to control rats, especially on days 14 and 21 during which EAE onset occurs. Responses to ConA in treated rats were normal or augmented, however, indicating lack of global immunosuppression.
  • lymph node cells were also unresponsive to the inventive lectin (data not shown), indicating that the lectin was not mitogenic
  • the sera of treated rats did not contain antibodies specific for the lectin as measured by ELISA.
  • T-cell lines were selected from the draining lymph nodes. Although GPBP- specific T-cell lines could be raised from the GPBP/CFA immunized control group, no responses were observed to GPBP and no lines could be established from the lectin- treated rats. In separate experiments, lectin added to established T-cell lines had no inhibitory effect, however. Taken together, the data show that the
  • inventive recombinant lectin is potent in preventing primary sensitization to both GPBP and PPD, but did not affect T-cell responses generally, as shown by full T-cell responses to ConA.
  • mice symptoms of EAE can be made to occur in cyclical fashion by boosting the animals with antigen following each cycle, and each cycle becomes more severe until death ultimately occurs.
  • This is a useful model in which to determine therapeutic efficacy, since it closely mimics both the chronic disease relapses and the acute demyelination associated with multiple sclerosis.
  • 20 female SJL/J mice were immunized with lyophilized spinal cord extract dissolved in PBS plus CFA on days 0, 7 and 21.
  • Ten mice were injected with recombinant lectin, and ten mice were given buffer only.
  • the lectin-treated mice received 50 ⁇ g lectin on days 13 and 15 intravenously in the tail vein, and an additional 100 ⁇ g i.v. daily from day 18 through day 24. Mice were followed until death or sacrifice at day 42.
  • a control group comprised twelve recipients treated daily i.v. only with buffer control.
  • the graft survival times were: 6d (x4), 7d (x7), and 8d, giving a mean survival of 6.82 + /-0.6d (SD).
  • the final day of survival is defined as the day on which the donor heart ceased to contract as assessed by lack of obvious palpitations and as confirmed by direct visualization at laparotomy.
  • mice Five recipients were treated with the recombinant lectin. All animals were pretreated with 1 mg/kg i.v. lectin on days -3, -2 and -1. The first two animals were then treated postoperatively with 1 mg/kg/d i.v. with lectin from day 1 until graft rejection. The second three animals were treated in the postoperative period from day 1 until graft rejection with 2 mg/kg/d i.v. of lectin. Graft survivals were 9 and 10d for the first group of rats, and 9, 10 and lid for the second group. No dramatic increase in survival was seen by doubling the dose of lectin in group two in the post- operative period. Therefore, graft survival times of both groups were combined for statistical analysis.
  • Cyclosporin i.p. was started the day of the graft and continued daily. Recombinant lectin was started two days prior to transplant and continued daily.
  • the number of survivors on day 16 are shown in Table 8.
  • the group receiving cyclosporin alone was unusually long lived, since animals on such therapy typically die within two weeks.
  • the combination therapy had a higher survivor rate than cyclosporin or lectin administered alone or the sum of the two survival rates.
  • the differences between control and test groups decreased, which may be attributed to 1) the unusually longevity of the
  • Phenotypes of Selected Rat Lymphocytes Table 11A shows a 28% increase in the number of rat lymph node suppressor T-cells (reactive with
  • Table 11B shows a 32% increase in the number of spleen suppressor T-cells as well as a 19% and 24% decrease in the numbers of helper T-cells (W3/25 antibody reactive, Serotec-Bioproducts) and total T-cells (w3/13 antibody reactive, Serotec-Bioproducts), respectively.
  • Human blood cells were pretreated with the inventive HL-60 lectin and then stained with
  • peripheral lymph nodes were removed from about half of the
  • lymph node cells were isolated on Ficol Hypaque density gradients.
  • the lymphoid cells (roughly 75% T cells, 20% of which were activated as assessed by IL-2 receptor expression, and the remainder B cells and macrophages) were radiolabelled with 111 indium, according to the method of Signore et al., Immunol. Lett. (1983) 6:151.
  • the labelled cells (about 10 x 10 6 cells per rat) were injected into the tail veins of the other half of the allograft recipients.
  • HL-60 lectin 250 ⁇ g was administered to 6 test animals at one half hour before labelled cell injection and again at three hours after labelled cell injection. Six hours after injection of the labelled cells, the organs were harvested and
  • the cells were labelled with
  • Test animals received HL-60 lectin, and control animals received vehicle alone.
  • inventive HL-60 lectin is inhibition of localization of lymphocytes into the lymph node, which is the site of immunization for alloantigens.
  • HL-60 lectin inhibits allograft rejection by decreasing the number of allospecific T cells which react with the graft.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Des compositions pharmaceutiques utiles dans le traitement des pathologies auto-immunes comportent, comme ingrédient actif, une lectine soluble d'un poids moléculaire d'environ 14 kilodaltons ou un des ses fragments. La lectine ou son fragment se lie à des fractions contenant du β-galactoside, indépendamment de la présence ou de l'absence de Ca+2, stimule l'hémagglutination des érythrocytes de lapin trypsinés dans des titrages de lectine standards où cette stimulation est inhibée par le lactose ou le thiogalactoside, comporte une séquence d'acide aminé qui contient au moins un site de N-glycosylation et se révèle au moins à 90 % homologue de la séquence d'acide aminé figurant aux positions 2-135 de la figure 1 ou de ses parties pertinentes. On utilise cette composition dans le traitement des pathologies auto-immunes telles que l'arthrite rhumatoïde, la myasthénie grave et la sclérose en plaques, ainsi que pour moduler la réponse immunitaire propre aux réactions allergiques ou aux rejets de greffes de tissus ou d'organes. La composition inventée peut être combinée avec des immunosuppresseurs d'usage général.
PCT/US1993/011107 1992-11-16 1993-11-16 Procede d'obtention d'une immunosuppression selective a l'aide de lectines apparentees a hl-60 WO1994011497A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU56085/94A AU5608594A (en) 1992-11-16 1993-11-16 Method of causing selective immunosuppression using hl-60-related lectins

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97692892A 1992-11-16 1992-11-16
US07/976,928 1992-11-16

Publications (1)

Publication Number Publication Date
WO1994011497A1 true WO1994011497A1 (fr) 1994-05-26

Family

ID=25524633

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1993/011107 WO1994011497A1 (fr) 1992-11-16 1993-11-16 Procede d'obtention d'une immunosuppression selective a l'aide de lectines apparentees a hl-60

Country Status (2)

Country Link
AU (1) AU5608594A (fr)
WO (1) WO1994011497A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998008535A2 (fr) * 1996-08-26 1998-03-05 Incyte Pharmaceuticals, Inc. Procede permettant de provoquer une immuno-suppression selective au moyen de lectines associees aux hl-60
WO1999012041A1 (fr) * 1997-09-05 1999-03-11 The Board Of Regents Of The University Of Oklahoma Composition et methodes utilisant la galectine-1
US6225071B1 (en) 1997-09-05 2001-05-01 The Board Of Regents Of The University Of Oklahoma Methods of screening for compounds which mimic galectin-1
WO1998002456A3 (fr) * 1996-07-15 2002-10-17 Incyte Pharmaceuticals, Inc. Nouvelle lectine humaine de type c
WO2009131435A1 (fr) * 2008-04-23 2009-10-29 Erasmus University Medical Center Rotterdam Lieur contenant de la bungarotoxine et un peptide de liaison
RU2528860C2 (ru) * 2008-10-29 2014-09-20 Леуколект Ас Лейколектины и их применение
RU2595823C2 (ru) * 2011-06-24 2016-08-27 Аква Био Текнолоджи Аса Способы получения косметической композиции, содержащей лейколектин, и ее применение
US9708380B2 (en) 2010-04-29 2017-07-18 Leukolect As Human leukolectins and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60184020A (ja) * 1984-03-02 1985-09-19 Seikagaku Kogyo Co Ltd ヒト由来レクチン及びその採取法
US5258287A (en) * 1988-03-22 1993-11-02 Genentech, Inc. DNA encoding and methods of production of insulin-like growth factor binding protein BP53

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60184020A (ja) * 1984-03-02 1985-09-19 Seikagaku Kogyo Co Ltd ヒト由来レクチン及びその採取法
US5258287A (en) * 1988-03-22 1993-11-02 Genentech, Inc. DNA encoding and methods of production of insulin-like growth factor binding protein BP53

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
E.A. RAWLINS, "Bentley's Textbook of Pharmaceutics", published 1978, by BAILLIERE TINDALL (LONDON), pages 186 and 192-194. *
EUROPEAN JOURNAL OF IMMUNOLOGY, Volume 13, issued 1983, LEVI et al., "Prevention and Therapy with Electrolectin of Experimental Autoimmune Myasthenia Gravis in Rabbits", pages 500-507. *
I.E. LIENER et al., "The Lectins: Properties, Functions, and Applications in Biology and Medicine", published 02 March 1986, by ACADEMIC PRESS (N.Y.), page 353. *
J.W. GODING, "Monoclonal Antibodies: Principles and Practice", published 1983, by ACADEMIC PRESS (N.Y.), pages 250-261. *
K. OLDEN et al., "Vertebrate Lectins", published 1987, by VAN NOSTRAND REINHOLD ADVANCED CELL BIOLOGY SERIES (N.Y.), pages 27-32. *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998002456A3 (fr) * 1996-07-15 2002-10-17 Incyte Pharmaceuticals, Inc. Nouvelle lectine humaine de type c
WO1998008535A2 (fr) * 1996-08-26 1998-03-05 Incyte Pharmaceuticals, Inc. Procede permettant de provoquer une immuno-suppression selective au moyen de lectines associees aux hl-60
WO1998008535A3 (fr) * 1996-08-26 1998-05-28 Incyte Pharma Inc Procede permettant de provoquer une immuno-suppression selective au moyen de lectines associees aux hl-60
WO1999012041A1 (fr) * 1997-09-05 1999-03-11 The Board Of Regents Of The University Of Oklahoma Composition et methodes utilisant la galectine-1
US6225071B1 (en) 1997-09-05 2001-05-01 The Board Of Regents Of The University Of Oklahoma Methods of screening for compounds which mimic galectin-1
WO2009131435A1 (fr) * 2008-04-23 2009-10-29 Erasmus University Medical Center Rotterdam Lieur contenant de la bungarotoxine et un peptide de liaison
RU2528860C2 (ru) * 2008-10-29 2014-09-20 Леуколект Ас Лейколектины и их применение
US9260498B2 (en) 2008-10-29 2016-02-16 Leukolect As Leukolectins and uses thereof
US10124034B2 (en) 2008-10-29 2018-11-13 Leukolect As Leukolectins and uses thereof
US9708380B2 (en) 2010-04-29 2017-07-18 Leukolect As Human leukolectins and uses thereof
RU2595823C2 (ru) * 2011-06-24 2016-08-27 Аква Био Текнолоджи Аса Способы получения косметической композиции, содержащей лейколектин, и ее применение
US10017552B2 (en) 2011-06-24 2018-07-10 Aqua Bio Technology Asa Methods of using a composition comprising leukolectin for cosmetic skin treatment
US10556937B2 (en) 2011-06-24 2020-02-11 Aqua Bio Technology Asa Methods for the production of a cosmetic composition comprising leukolectin and uses thereof

Also Published As

Publication number Publication date
AU5608594A (en) 1994-06-08

Similar Documents

Publication Publication Date Title
US5693760A (en) Method of causing selective immunosuppression using HL-60 related lectins
EP0764030B1 (fr) Composition contenant d'autoanticorps pour la therapie et la prophylaxie antitumorale
US6325999B1 (en) Use of Fas ligand to suppress T-lymphocyte-mediated immune responses
KR19990063648A (ko) 글루타민산 데카복실라제에 대한 항체와 폴리(에틸렌 글리콜)공액물을 섬세포에 제공하는 방법
US5587460A (en) 14-beta-gal mammalian lectins
Cotmore et al. Purification of Thy‐1‐related glycoproteins from human brain and fibroblasts: comparisons between these molecules and murine glycoproteins carrying Thy‐1.1 and Thy‐1.2 antigens
WO1996023882A9 (fr) IDENTIFICATION DE LA PROTEINE MEMBRANAIRE, INTEGRALE DEC (CELLULES DENDRITIQUES ET EPITHELIALES, 205 kDa), UN RECEPTEUR A DOMAINES LECTINIQUES DE TYPE C, DES ACIDES NUCLEIQUES CODANT DEC, AINSI QUE SES APPLICATIONS
JPH08505764A (ja) 腫瘍血管内皮細胞に特異的に結合するモノクローナル抗体とその利用方法
IBRAHIM et al. Reproductive tract secretions and bull spermatozoa contain different clusterin isoforms that cluster cells and inhibit complement‐induced cytolysis
JPH10513347A (ja) 組換え型ヒトα−フェトプロテインおよびその利用
Beneski et al. Human retinal S-antigen. Isolation, purification, and characterization.
WO1994011497A1 (fr) Procede d'obtention d'une immunosuppression selective a l'aide de lectines apparentees a hl-60
JP2001523249A (ja) 特異的免疫寛容を誘導するための抗原と粘膜結合成分の組合せ
US7332592B2 (en) Isolated recombinant bovine soluble CD14 polypeptide, rbosCD14
EP0303463B1 (fr) Méthode pour contrôler l'extravasation des leucocytes
US5580561A (en) Methods and pharmaceutical compositions for blocking suppression of immune defense mechanisms using an antibody, a factor, or an antisense peptide
US6406679B1 (en) Use of HL-60-related lectins in drug delivery and detection of lectin-expressing cells
JPH09502089A (ja) ナチュラルキラー細胞特異性抗原およびこの抗原を識別する抗体
WO2002100343A2 (fr) Galectine-3, tronquee au niveau de son extremite n-terminale, a liberation prolongee et anticorps aux ligands glucidiques de la galectine-3 a utiliser dans le traitement du cancer
US20040052780A1 (en) Immunosuppresants
US20050032673A1 (en) Sustained release N-terminally truncated galectin-3 and antibodies to galectin-3 carbohydrate ligands for use in treating disease
JP2002516339A (ja) ＬＡＩＴ／ｓＣＤ１４−蛋白質による抗生物質蛋白質およびペプチドの誘導
WO2000071147A1 (fr) Nouvelle utilisation therapeuthique de la proteine modulatrice de l'inflammation virale pour bloquer le rejet d'une xenogreffe
JPH10212230A (ja) Ｈｓｐ６０ファミリーに属するタンパク質のジヒドロキシナフトキノン化合物含有合成抑制剤
WO1998008535A2 (fr) Procede permettant de provoquer une immuno-suppression selective au moyen de lectines associees aux hl-60

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载